Wernicke-Korsakoff-like syndrome in patients with colorectal carcinoma treated with high-dose doxifluridine (5'-dFUrd)
- PMID: 2941966
- DOI: 10.1111/j.1600-0404.1986.tb04583.x
Wernicke-Korsakoff-like syndrome in patients with colorectal carcinoma treated with high-dose doxifluridine (5'-dFUrd)
Abstract
5'-dFUrd (doxifluridine) is a new fluoropyrimidine that may have a higher antitumor effect and less side effects than 5-FU. In this study 15 patients with advanced colorectal carcinoma, one with renal carcinoma, one with carcinoid and one with advanced carcinoma of unknown origin, were randomly assigned to receive 5'-dFUrd 5 g/m2 or 3 g/m2 as a 1-h infusion for 5 days in 3 cycles at intervals of 4 weeks. The patients had repeated neurological and neurophysiological examinations before and during the treatment. Ten patients developed symptoms of toxicity of the central nervous system (CNS), with cerebellopathy and encephalopathy resembling a Wernicke-Korsakoff syndrome. The neurotoxicity was dose related, affecting 7 of 8 patients in the high dosage group and 3 of 9 patients in the low dosage group. The symptoms generally started at the end of the second week of the cycle with unsteadiness and diplopia, and progressed to the fourth week with ataxia, confusion and EEG-changes, becoming more pronounced with increasing number of cycles. After the treatment there was normalisation within 4-8 weeks. Cachectic patients and patients with a pathological EEG before treatment seem to represent a high-risk group for CNS-symptoms. EEG may be helpful in early diagnosis of CNS-toxicity.
Similar articles
-
Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study.Cancer Chemother Pharmacol. 1985;15(2):161-3. doi: 10.1007/BF00257528. Cancer Chemother Pharmacol. 1985. PMID: 2990750
-
Phase I/II tolerability/pharmacokinetic study with one-hour intravenous infusion of doxifluiridine (5'-dFUrd) 3 g/m2 VS 5 g/m2 QD x 5 per month.Cancer Chemother Pharmacol. 1986;18(3):252-6. doi: 10.1007/BF00273397. Cancer Chemother Pharmacol. 1986. PMID: 2948731 Clinical Trial.
-
Neurological manifestations in a phase 2 study of 13 patients treated with doxyfluridine.Acta Neurol Scand. 1985 Aug;72(2):171-5. doi: 10.1111/j.1600-0404.1985.tb00859.x. Acta Neurol Scand. 1985. PMID: 2996281
-
Phase I-II trial of doxifluridine (5'DFUR) administered as long-term continuous infusion using a portable infusion pump for advanced colorectal cancer.Eur J Cancer Clin Oncol. 1989 Nov;25(11):1543-8. doi: 10.1016/0277-5379(89)90295-2. Eur J Cancer Clin Oncol. 1989. PMID: 2531670
-
Chapter 30: historical aspects of the major neurological vitamin deficiency disorders: the water-soluble B vitamins.Handb Clin Neurol. 2010;95:445-76. doi: 10.1016/S0072-9752(08)02130-1. Handb Clin Neurol. 2010. PMID: 19892133 Review.
Cited by
-
Thiamine deficiency and Wernicke's encephalopathy in AIDS.Metab Brain Dis. 1991 Dec;6(4):207-12. doi: 10.1007/BF00996920. Metab Brain Dis. 1991. PMID: 1812394
-
Human urinary excretion of doxifluridine and metabolites during a 5-day chemotherapeutic schedule using fluorine-19 nuclear magnetic resonance spectrometry.Invest New Drugs. 1987;5(3):273-9. doi: 10.1007/BF00175298. Invest New Drugs. 1987. PMID: 2959633
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical